Last $77.12 USD
Change Today -1.59 / -2.02%
Volume 175.3K
FURX On Other Exchanges
As of 8:10 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

furiex pharmaceuticals (FURX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/4/14 - $121.97
52 Week Low
05/10/13 - $32.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

furiex pharmaceuticals (FURX) Related Businessweek News

No Related Businessweek News Found

furiex pharmaceuticals (FURX) Details

Furiex Pharmaceuticals, Inc. operates as a drug development company that is involved in compound development and collaboration activities primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company holds rights to royalties and regulatory and sales-based milestone payments for alogliptin, alogliptin combination products, and SYR-472 (trelagliptin) for the treatment of Type-2 diabetes, which are marketed under the Nesina and Liovel names in Japan, as well as under the Nesina, Oseni, and Kazano names in the United States. It also owns rights to royalties and sales-based milestones for Priligy (dapoxetine) for premature ejaculation, which is marketed in approximately 30 countries in Europe, the Asia-Pacific, and Latin America. In addition, the company holds license rights to eluxadoline (MuDelta), a novel, orally active, investigational agent, which is in Phase III development diarrhea-predominant irritable bowel syndrome, and to JNJ-Q2, a novel, fluoroquinolone antibiotic, which is in Phase III development for skin and lung infections. It markets its products through third party collaborators. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.

24 Employees
Last Reported Date: 03/17/14
Founded in 1998

furiex pharmaceuticals (FURX) Top Compensated Officers

President, Chief Medical Officer and Director
Total Annual Compensation: $379.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $241.3K
Senior Vice President of Clinical Development...
Total Annual Compensation: $313.9K
Senior Vice President of Research
Total Annual Compensation: $287.3K
Compensation as of Fiscal Year 2013.

furiex pharmaceuticals (FURX) Key Developments

Furiex Puts Itself On The Block

Furiex Pharmaceuticals, Inc. (NasdaqGS:FURX) has reportedly hired Bank of America Corp to find a buyer. Bloomberg reported that Salix Pharmaceuticals Ltd. (NasdaqGS:SLXP), Actavis plc (NYSE:ACT) and Takeda Pharmaceutical Company Limited (TSE:4502) to be potential buyers for Furiex. Tony Plohoros, representative for Furiex, declined to comment. G. Michael Freeman, spokesman for Salix, said the company had no comment when asked if it was considering an acquisition of Furiex. Representatives for Actavis and Takeda declined to comment when asked if they were considering an acquisition of Furiex.

Furiex Pharmaceuticals Considers Strategic Options

Furiex Pharmaceuticals, Inc. (NasdaqGS:FURX) considers strategic options. Furiex's Chairman, Fred Eshelman, said "We continue to evaluate all strategic options that might be available for the company." Possibilities cited by the company include launching on its own its experimental treatment for irritable bowel syndrome, eluxadoline, after obtaining regulatory approval; as well as possibly seeking a strategic partnership. "I don't think we have ruled anything off the table," Eshelman said. Furiex shares closed at $87.87, down $5.36.

Furiex Pharmaceuticals, Inc. Announces Revenue Guidance for the Year 2014

Furiex Pharmaceuticals, Inc. announced revenue guidance for the year 2014. For the year, the company expects royalty revenue in total to increase in 2014 year-over-year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FURX:US $77.12 USD -1.59

FURX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 3,759 GBp +35.50
Eli Lilly & Co $59.96 USD +0.54
Merck & Co Inc $56.26 USD +0.21
Novartis AG SFr.74.35 CHF +0.80
View Industry Companies

Industry Analysis


Industry Average

Valuation FURX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.4x
Price/Book 44.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.8x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FURIEX PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at